About OOO MO New Hospital
Clinical Trials at OOO MO New Hospital
During the past decade, OOO MO New Hospital conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on
average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at OOO MO New Hospital
According to Clinical.Site data, the most researched conditions in "OOO MO New Hospital" are
"Crohn Disease" (1 trials) and "Ulcerative Colitis" (1 trials). Many other conditions were trialed in "OOO MO New Hospital" in a lesser frequency.
Clinical Trials Intervention Types at OOO MO New Hospital
Most popular intervention types in "OOO MO New Hospital" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.
The name of intervention was led by "Adalimumab (40 mg)" (1 trials), "Guselkumab" (1 trials), "Placebo" (1 trials), "Placebo for Adalimumab" (1 trials) and "Placebo for Ustekinumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at OOO MO New Hospital
The vast majority of trials in "OOO MO New Hospital" are
2 trials for "All" genders.
Clinical Trials Status at OOO MO New Hospital
Currently, there are NaN active trials in "OOO MO New Hospital".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in OOO MO New Hospital,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in OOO MO New Hospital, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".